Shenzhen Xinyue Biotech closes Series Pre-A round; Legend, Ubrigene
Elise Mak · 07/08/2022
Shenzhen Xinyue Biotech, founded in April 2021, closed a Series Pre-A round to speed up the development of its DNA encoded library (DEL)3.0 technology platform and its oncology pipeline. More news from Legend, Ubrigene.
ProfoundBio nabs $70M in Series A+ to move ADCs to clinical trials; Evive, Lee's Pharma, CStone
Elise Mak · 06/06/2022
ProfoundBio has raised $70 million in a Series A+ round led by Sequoia China to move two antibody-drug conjugate programs, PRO1184 and PRO1160, into clinical trials. More news from Evive, Lee's Pharma, CStone, Legend, CanSino.
Legend Biotech's BCMA-targeted CAR-T cell therapy wins approval in Europe; HemaCell, Gracell, Adagene
Elise Mak · 05/27/2022
Legend Biotech's Carvykti has been granted conditional marketing authorization by the European Commission for the treatment of adults with relapsed and refractory multiple myeloma. More news from HemaCell, GSK, Gracell, Adagene.
METiS Pharmaceuticals raises $150M to promote AI in drug discovery and delivery; Kintor, Raymon, Arthur Group
Elise Mak · 04/06/2022
METiS Pharmaceuticals, which uses AI to aid drug discovery and targeted delivery, closed two financing rounds to raise a total of $150 million. More news from Kintor, Raymon, Arthur Group, Innovent, PREGENE, Fosun Pharma, Junshi Biosciences and Legend Biotech.
BeiGene launches $3.5B IPO on Shanghai’s STAR market; Leads Biolabs, Simcere, Legend - News of the day
Elise Mak · 12/15/2021
Chinese biotech firm BeiGene becomes the world’s first stock to list in the U.S., Hong Kong and mainland China, and more news from Leads Biolabs, Simcere, Legend Biotech, Lupeng Pharmaceutical, Lupeng Pharmaceutical, Ascentage, Antengene and the CDE.
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback:   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement